468741-20-0Relevant academic research and scientific papers
Discovery of a 1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity
Wittman, Mark,Carboni, Joan,Attar, Ricardo,Balasubramanian, Balu,Balimane, Praveen,Brassil, Patrick,Beaulieu, Francis,Chang, Chiehying,Clarke, Wendy,Dell, Janet,Eummer, Jeffrey,Frennesson, David,Gottardis, Marco,Greer, Ann,Hansel, Steven,Hurlburt, Warren,Jacobson, Bruce,Krishnananthan, Subramaniam,Lee, Francis Y.,Li, Aixin,Lin, Tai-An,Liu, Peiying,Ouellet, Carl,Sang, Xiaopeng,Saulnier, Mark G.,Stoffan, Karen,Sun, Yax,Velaparthi, Upender,Wong, Henry,Yang, Zheng,Zimmermann, Kurt,Zoeckler, Mary,Vyas, Dolatrai
, p. 5639 - 5643 (2007/10/03)
Compound 3 (BMS-536924), a novel small-molecule inhibitor of the insulin-like growth factor receptor kinase with equal potency against the insulin receptor is described. The in vitro and in vivo biological activity of this interesting compound is also rep
Benzimidazole C-2 heterocycles as kinase inhibitors
-
Page/Page column 17, (2010/02/11)
Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.
Novel tyrosine kinase inhibitors
-
Page 32, (2010/11/30)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
